# OPALINE : A Study Of Morbidity And Mortality At 2 Years

> **NCT02264665** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 144 (actual)

## Conditions studied

- Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive

## Interventions

- **DRUG:** sunitinib
- **DRUG:** everolimus
- **DRUG:** chemotherapies recommended in france

## Key facts

- **NCT ID:** NCT02264665
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-12
- **Primary completion:** 2019-11-18
- **Final completion:** 2019-11-18
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2023-11-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264665, "OPALINE : A Study Of Morbidity And Mortality At 2 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02264665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*